<p>隨着全球市場在波動的利率和經濟指標的複雜環境中航行，小盤股展現出韌性，受益於近期對潛在降息的希望。在這種環境下，識別未被發現的投資機會變得至關重要，因為這些股票通常具有獨特的增長潛力，並能在更廣泛的市場不確定性中蓬勃發展。</p>
<h3>全球十大基本面強勁的未被發現的投資機會</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>獅子巖集團</td>
<td>5.00%</td>
<td>14.21%</td>
<td>13.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品國際控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>6.95%</td>
<td>4.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>達芙妮國際控股</td>
<td>NA</td>
<td>-5.92%</td>
<td>82.03%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>HG 金屬製造</td>
<td>3.75%</td>
<td>8.47%</td>
<td>6.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>太洋化學有限公司</td>
<td>0.67%</td>
<td>5.77%</td>
<td>2.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中國新城市集團</td>
<td>85.52%</td>
<td>30.33%</td>
<td>17.38%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>李銘發展建設</td>
<td>170.96%</td>
<td>14.13%</td>
<td>22.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Practic</td>
<td>NA</td>
<td>4.86%</td>
<td>6.64%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球基本面強勁的未被發現的投資機會篩選器中的 2946 只股票的完整列表。</p>
<p>我們將從我們的篩選結果中考察一些選項。</p>
<h2>上海耀華皮爾金頓玻璃集團 (SHSE:600819)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 上海耀華皮爾金頓玻璃集團有限公司在玻璃製造行業運營，市值為 54.1 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其玻璃製造業務產生收入。淨利潤率顯示出波動，反映出運營效率和市場條件的變化。</p>
<p>作為玻璃行業中的小型參與者，上海耀華皮爾金頓玻璃集團展現出令人印象深刻的財務韌性。最近，其盈利增長了 282.5%，遠超基礎材料行業的 21.2% 增長率。公司的負債權益比在五年內顯著改善，從 21% 降至 12.2%，表明其財務管理謹慎。儘管截至 2025 年 6 月的半年銷售額從 27.5 億人民幣下降至 26.18 億人民幣，但淨收入從去年的 6300 萬人民幣上升至 8600 萬人民幣。由於利息支付由 EBIT 以 19 倍的強勁倍數覆蓋，且報告的盈利質量高，上海耀華似乎在市場波動中有望保持穩定。</p>
<ul>
<li>通過我們的綜合健康報告深入瞭解上海耀華皮爾金頓玻璃集團的複雜情況。</li>
<li>探索歷史數據，以跟蹤上海耀華皮爾金頓玻璃集團的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b06a1b8b-78d5-4a8f-b6fd-257b19781141/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b06a1b8b-78d5-4a8f-b6fd-257b19781141/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 SHSE:600819 負債權益比</p>
<h2>振德醫療 (SHSE:603301)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 振德醫療有限公司專注於中國醫療護理和防護設備的研究、開發、生產和銷售，市值為 71.9 億人民幣。</p>
<p><strong>運營：</strong> 振德醫療通過銷售醫療護理和防護設備產生收入。公司的財務表現以淨利潤率為特徵，反映其運營效率。</p>
<p>作為醫療設備行業中的小型參與者，振德醫療在過去一年中展現出 188% 的令人印象深刻的盈利增長，超越了行業同行。儘管 2025 年上半年淨收入較去年的 1.6111 億人民幣下降至 1.2776 億人民幣，但其債務管理強勁，利息支付由 EBIT 覆蓋 341 倍，負債權益比在五年內從 32.3% 降至 24%。以被認為低於公允價值 32% 的價格交易，表明潛在的上漲空間，同時其在沙特的合資工廠等戰略舉措增強了區域市場的存在感和未來前景。</p>
<ul>
<li>在此健康報告中解鎖我們對振德醫療股票分析的全面見解。</li>
<li>通過檢查我們的歷史報告瞭解振德醫療的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f41794d2-9dc2-480b-8e63-913d5fdf0722/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f41794d2-9dc2-480b-8e63-913d5fdf0722/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 SHSE:603301 負債權益比</p>
<h2>Convano (TSE:6574)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Convano Inc. 在日本經營美甲沙龍的管理和特許經營，市值為 1031.7 億日元。</p>
<p><strong>運營：</strong> Convano 主要通過其美甲業務產生收入，貢獻 30.9 億日元，此外，醫療保健和投資顧問部門分別貢獻 1.0041 億日元和 5529 萬日元。</p>
<p>Convano 已成為一個充滿活力的參與者，最近實現了盈利，並展現出強勁的財務健康。公司的負債權益比在五年內顯著下降，從 45.9% 降至 20.5%，表明其有效的債務管理。儘管最近幾個月股價波動劇烈，但利息支付由 EBIT 以 17.9 倍的倍數覆蓋，Convano 的財務穩定性顯而易見。該公司完成了一次重大股票拆分和私募，籌集了 60 億日元用於戰略舉措，行使期延長至 2027 年 7 月。這些發展表明 Convano 正在為未來的行業增長做好準備。</p>
<ul>
<li>在此深入瞭解 Convano 的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 Convano 過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5c2da5f-4530-48cb-af0c-006c3ddd465b/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5c2da5f-4530-48cb-af0c-006c3ddd465b/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 TSE:6574 負債權益比</p>
<h2>下一步</h2>
<ul>
<li>在這裏開始您的投資之旅，探索我們 2946 個具有強大基本面的全球未被發現的投資寶藏。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過使用 Simply Wall St，加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
<h2>尋找其他投資機會？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力可觀但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

振德醫療

<p>這篇文章討論了小盤股在波動的全球市場中的韌性，強調了上海耀華皮爾金頓玻璃集團和振德醫療作為有前景的投資。上海耀華展現了 282.5% 的令人印象深刻的盈利增長和改善的債務管理，而振德醫療則在淨收入略有下降的情況下報告了 188% 的盈利增長。這兩家公司都具備穩定和增長的潛力，強大的基本面和戰略舉措增強了它們的市場存在感。文章強調了在當前經濟環境中識別未被發現的投資機會的重要性</p>

<p>As global markets navigate a complex landscape marked by fluctuating interest rates and economic indicators, smaller-cap stocks have shown resilience, benefiting from recent hopes of potential rate cuts. In this environment, identifying undiscovered gems becomes crucial, as these stocks often possess unique growth potential and can thrive amid broader market uncertainties.</p>
<div class="lb-trans"><p>隨着全球市場在波動的利率和經濟指標的複雜環境中航行，小盤股展現出韌性，受益於近期對潛在降息的希望。在這種環境下，識別未被發現的投資機會變得至關重要，因為這些股票通常具有獨特的增長潛力，並能在更廣泛的市場不確定性中蓬勃發展。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大基本面強勁的未被發現的投資機會</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lion Rock Group</td>
<td>5.00%</td>
<td>14.21%</td>
<td>13.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Natural Food International Holding</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>6.95%</td>
<td>4.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daphne International Holdings</td>
<td>NA</td>
<td>-5.92%</td>
<td>82.03%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>HG Metal Manufacturing</td>
<td>3.75%</td>
<td>8.47%</td>
<td>6.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Taiyo KagakuLtd</td>
<td>0.67%</td>
<td>5.77%</td>
<td>2.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI Advanced Systems</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>China New City Group</td>
<td>85.52%</td>
<td>30.33%</td>
<td>17.38%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Li Ming Development Construction</td>
<td>170.96%</td>
<td>14.13%</td>
<td>22.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Practic</td>
<td>NA</td>
<td>4.86%</td>
<td>6.64%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>獅子巖集團</td>
<td>5.00%</td>
<td>14.21%</td>
<td>13.26%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品國際控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>6.95%</td>
<td>4.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>達芙妮國際控股</td>
<td>NA</td>
<td>-5.92%</td>
<td>82.03%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>HG 金屬製造</td>
<td>3.75%</td>
<td>8.47%</td>
<td>6.94%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>太洋化學有限公司</td>
<td>0.67%</td>
<td>5.77%</td>
<td>2.06%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>33.93%</td>
<td>20.38%</td>
<td>21.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中國新城市集團</td>
<td>85.52%</td>
<td>30.33%</td>
<td>17.38%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>李銘發展建設</td>
<td>170.96%</td>
<td>14.13%</td>
<td>22.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Practic</td>
<td>NA</td>
<td>4.86%</td>
<td>6.64%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 2946 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球基本面強勁的未被發現的投資機會篩選器中的 2946 只股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從我們的篩選結果中考察一些選項。</p>
</div><h2>Shanghai Yaohua Pilkington Glass Group (SHSE:600819)</h2>
<div class="lb-trans"><h2>上海耀華皮爾金頓玻璃集團 (SHSE:600819)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shanghai Yaohua Pilkington Glass Group Co., Ltd. operates in the glass manufacturing industry and has a market capitalization of CN¥5.41 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海耀華皮爾金頓玻璃集團有限公司在玻璃製造行業運營，市值為 54.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its glass manufacturing operations. The net profit margin has shown fluctuations, reflecting changes in operational efficiency and market conditions.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其玻璃製造業務產生收入。淨利潤率顯示出波動，反映出運營效率和市場條件的變化。</p>
</div><p>Shanghai Yaohua Pilkington Glass Group, a smaller player in the glass industry, has shown impressive financial resilience. Recently, its earnings surged by 282.5%, far outpacing the Basic Materials industry's 21.2% growth rate. The company's debt to equity ratio improved significantly from 21% to 12.2% over five years, indicating prudent financial management. Despite a slight dip in sales from CNY 2,750 million to CNY 2,618 million for the half-year ending June 2025, net income rose to CNY 86 million from CNY 63 million last year. With interest payments well covered by EBIT at a robust factor of 19x and high-quality earnings reported, Shanghai Yaohua seems poised for continued stability amidst market fluctuations.</p>
<div class="lb-trans"><p>作為玻璃行業中的小型參與者，上海耀華皮爾金頓玻璃集團展現出令人印象深刻的財務韌性。最近，其盈利增長了 282.5%，遠超基礎材料行業的 21.2% 增長率。公司的負債權益比在五年內顯著改善，從 21% 降至 12.2%，表明其財務管理謹慎。儘管截至 2025 年 6 月的半年銷售額從 27.5 億人民幣下降至 26.18 億人民幣，但淨收入從去年的 6300 萬人民幣上升至 8600 萬人民幣。由於利息支付由 EBIT 以 19 倍的強勁倍數覆蓋，且報告的盈利質量高，上海耀華似乎在市場波動中有望保持穩定。</p>
</div><ul>
<li>Navigate through the intricacies of Shanghai Yaohua Pilkington Glass Group with our comprehensive health report here.</li>
<li>Explore historical data to track Shanghai Yaohua Pilkington Glass Group's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合健康報告深入瞭解上海耀華皮爾金頓玻璃集團的複雜情況。</li>
<li>探索歷史數據，以跟蹤上海耀華皮爾金頓玻璃集團的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b06a1b8b-78d5-4a8f-b6fd-257b19781141/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b06a1b8b-78d5-4a8f-b6fd-257b19781141/chart/debt-equity-history-analysis"/></p>
<p>SHSE:600819 Debt to Equity as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:600819 負債權益比</p>
</div><h2>Zhende Medical (SHSE:603301)</h2>
<div class="lb-trans"><h2>振德醫療 (SHSE:603301)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhende Medical Co., Ltd. focuses on the research, development, production, and sale of medical care and protective equipment in China with a market capitalization of CN¥7.19 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 振德醫療有限公司專注於中國醫療護理和防護設備的研究、開發、生產和銷售，市值為 71.9 億人民幣。</p>
</div><p><strong>Operations:</strong> Zhende Medical generates revenue from the sale of medical care and protective equipment. The company's financial performance is characterized by a net profit margin that reflects its operational efficiency.</p>
<div class="lb-trans"><p><strong>運營：</strong> 振德醫療通過銷售醫療護理和防護設備產生收入。公司的財務表現以淨利潤率為特徵，反映其運營效率。</p>
</div><p>Zhende Medical, a smaller player in the medical equipment sector, has shown impressive earnings growth of 188% over the past year, outpacing industry peers. Despite a dip in net income to CN¥127.76 million for the first half of 2025 compared to CN¥161.11 million last year, its debt management is strong with interest payments covered 341 times by EBIT and a reduced debt-to-equity ratio from 32.3% to 24% over five years. Trading at a value perceived as 32% below fair value suggests potential upside while its strategic ventures like the Saudi joint factory enhance regional market presence and future prospects.</p>
<div class="lb-trans"><p>作為醫療設備行業中的小型參與者，振德醫療在過去一年中展現出 188% 的令人印象深刻的盈利增長，超越了行業同行。儘管 2025 年上半年淨收入較去年的 1.6111 億人民幣下降至 1.2776 億人民幣，但其債務管理強勁，利息支付由 EBIT 覆蓋 341 倍，負債權益比在五年內從 32.3% 降至 24%。以被認為低於公允價值 32% 的價格交易，表明潛在的上漲空間，同時其在沙特的合資工廠等戰略舉措增強了區域市場的存在感和未來前景。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Zhende Medical stock in this health report.</li>
<li>Understand Zhende Medical's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此健康報告中解鎖我們對振德醫療股票分析的全面見解。</li>
<li>通過檢查我們的歷史報告瞭解振德醫療的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f41794d2-9dc2-480b-8e63-913d5fdf0722/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/f41794d2-9dc2-480b-8e63-913d5fdf0722/chart/debt-equity-history-analysis"/></p>
<p>SHSE:603301 Debt to Equity as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:603301 負債權益比</p>
</div><h2>Convano (TSE:6574)</h2>
<div class="lb-trans"><h2>Convano (TSE:6574)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Convano Inc. operates in the management and franchising of nail salons in Japan with a market capitalization of ¥103.17 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Convano Inc. 在日本經營美甲沙龍的管理和特許經營，市值為 1031.7 億日元。</p>
</div><p><strong>Operations:</strong> Convano generates revenue primarily from its Nail Business, which contributes ¥3.09 billion, supplemented by the Healthcare and Investment and Advisory segments with ¥100.41 million and ¥55.29 million respectively.</p>
<div class="lb-trans"><p><strong>運營：</strong> Convano 主要通過其美甲業務產生收入，貢獻 30.9 億日元，此外，醫療保健和投資顧問部門分別貢獻 1.0041 億日元和 5529 萬日元。</p>
</div><p>Convano has emerged as a dynamic player, recently achieving profitability and showcasing robust financial health. The company's debt to equity ratio impressively decreased from 45.9% to 20.5% over five years, indicating effective debt management. With interest payments well covered by EBIT at 17.9 times, Convano's financial stability is evident despite a highly volatile share price in recent months. The firm completed a significant stock split and private placement, raising ¥6 billion for strategic initiatives with an exercise period extending until July 2027. These developments suggest Convano is positioning itself for future growth within its industry landscape.</p>
<div class="lb-trans"><p>Convano 已成為一個充滿活力的參與者，最近實現了盈利，並展現出強勁的財務健康。公司的負債權益比在五年內顯著下降，從 45.9% 降至 20.5%，表明其有效的債務管理。儘管最近幾個月股價波動劇烈，但利息支付由 EBIT 以 17.9 倍的倍數覆蓋，Convano 的財務穩定性顯而易見。該公司完成了一次重大股票拆分和私募，籌集了 60 億日元用於戰略舉措，行使期延長至 2027 年 7 月。這些發展表明 Convano 正在為未來的行業增長做好準備。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Convano.</li>
<li>Review our historical performance report to gain insights into Convano's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此深入瞭解 Convano 的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 Convano 過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5c2da5f-4530-48cb-af0c-006c3ddd465b/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b5c2da5f-4530-48cb-af0c-006c3ddd465b/chart/debt-equity-history-analysis"/></p>
<p>TSE:6574 Debt to Equity as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 TSE:6574 負債權益比</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Embark on your investment journey to our 2946 Global Undiscovered Gems With Strong Fundamentals selection here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏開始您的投資之旅，探索我們 2946 個具有強大基本面的全球未被發現的投資寶藏。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過使用 Simply Wall St，加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>尋找其他投資機會？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力可觀但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

全球未被發現的寶石，重點介紹上海耀華皮爾金頓玻璃集團及兩個有潛力的小型股